Sema4 Securities Settlement

If, during the period between January 18, 2022 and August 15, 2022, inclusive, you purchased the publicly traded common stock and/or warrants of Sema4 Holdings Corp. n/k/a GeneDx Holdings Corp. (the “Company”), and/or purchased publicly traded call options on Company common stock, and/or wrote publicly traded put options on Company common stock for the beneficial interest of a person or entity other than yourself, please read the Broker/Nominee letter below with instructions on how to notify your clients:

If you are filing electronic claims:

Representatives with authority to file on behalf of (a) accounts of multiple Settlement Class Members and/or (b) institutional accounts with large numbers of transactions (“Representative Filers”) must submit information regarding their transactions in an electronic spreadsheet format. The instructions and spreadsheet template are below: